Lymphoma is catch-all term for up to 40 different types of cancer that all arise from white blood cells known as lymphocytes. Lymphoma is commonly split into two types: Hodgkin and non-Hodgkin lymphoma, with non-Hodgkin accounting for about 80% of cases.
Both Hodgkin and non-Hodgkin lymphoma are caused by cancerous white blood cells in the lymph nodes. The two types can only be differentiated when looking at cells from the lymph node under a microscope as they affect different types of white blood cells. Hodgkin lymphoma can be distinguished by the presence of Reed-Sternberg cells.
Hodgkin lymphoma typically affects people in early adulthood (15-40 years old) and late adulthood (over 55 years old). While non-Hodgkin lymphoma is mostly seen in adults over 65, it is among the most common cancers in children.
Survival rates vary significantly depending on the type and stage of the disease, as well as the age of the patient, however rates have increased dramatically over the past three decades. The standard treatments are radiotherapy and/or chemotherapy, but there have been numerous advances made in recent years.
Chemotherapy and radiotherapy are often used to destroy the cancerous white blood cells; however these also kill the functioning immune cells, as well as the stem cells that can produce more. To fix this after treatment, patients can receive a transplant of haematopoietic stem cells that are found in bone marrow.
As recently as 1970s, bone marrow transplants were thought to be impossible. All attempts to do so resulted in death from infections or immune reactions. This was unexpected after successful trials in rodents, however this may have been due to the inbred nature of the laboratory specimens.
Don Thomas, who won the Nobel Prize for his work in 1990, experimented with dogs, which have similar genetic variation as humans and can develop blood diseases such as non-Hodgkin lymphoma. He developed a procedure involving radiation to destroy the cancer, matching the tissue between donor and recipient, and drug cocktails to suppress the immune system. Although initial survival rates were low, gradual progress in anti-rejection drugs allowed for transplant from non-related donors by 1979.
Recently, Meloxicam, an aspirin-like drug, has been shown to encourage stem cells to leave bone marrow following a transplant, which can be a particular problem for non-Hodgkin lymphoma. This was first tested in mice and baboons before now being currently in human trials.
To avoid destroying the haematopoietic stem cells, monoclonal antibodies can be used to specifically target the lymphocyte white blood cells, including the malignant cells that cause the lymphoma. The antibodies recognise these cells and latch onto them, which recruits other parts of the immune system to destroy the cell. Campath 1-H, or alemtuzumab, is a humanised rat antibody which was first successfully used in 1988 to treat non-Hodgkin lymphoma.The original rat antibody was rejected by the immune system and was destroyed itself, but through genetic engineering techniques researchers took the important recognition regions from the rat antibody and placed it into the gene for the human antibody. This ground-breaking approach has since been applied to other cancers, and Campath itself is now being investigated as a multiple sclerosis treatment.
Rituxan, or rituximab, is now one of the standard treatments for lymphoma and is based on the same principle as Campath.
Antibodies have also been used to direct sources of radiation to cancer cells and target them more efficiently. Both Zevalin (ibritumonab tiuxetan) and Bexxar (tositumomab) were pioneering drugs approved in the early 2000s. These were formed from radioactive isotopes attached to mouse antibodies that recognise and bind to cancer cells. They are very potent treatments and are even effective in cancers that are resistant to Rituxan.
Unlike most vaccines that aim to prevent a disease, a lymphoma vaccine aims to stimulate the immune system into attacking the cancerous cells that are already present.
The vaccine is currently targeted at follicular lymphoma, the most common form of low grade lymphoma. The cancer tends to go in cycles of remission and relapse as it develops resistance to different treatments. The vaccine is designed to be used at early stages or when the cancer is in remission in order to target the remaining cells. This approach increases the time between relapses from 30 months to 44 months.
In 2012, the FDA said that it would not approve the vaccine for use in the US without further trials, resulting in the bankruptcy of the manufacturer. However, the vaccine is still expected to get market approval in Europe and Canada in late 2014.
- Hoggatt J et al (2013) Differential stem- and progenitor-cell trafficking by prostaglandin E2 Nature 495:365–369 doi:10.1038/nature11929
- Riechmann L, Clark M, Waldmann H, Winter G. (1988) Reshaping human antibodies for therapy. Nature 332:323-7 doi:10.1038/332323a0
- Cohen JA et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial The Lancet 380(9856):1819-1828 doi:10.1016/S0140-6736(12)61769-3
- Coles AJ et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial The Lancet 380(9856):1829-1839 doi:10.1016/S0140-6736(12)61768-1
- Scott SD (1998) Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma Cancer Pract 6(3): 195–7. doi:10.1046/j.1523-5394.1998.006003195.x
- Saini KS et al (2011) Rituximab in Hodgkin lymphoma: Is the target always a hit? Cancer Treat Rev 37 (5): 385–90 doi:10.1016/j.ctrv.2010.11.005
- Milenic DE, Brady ED and Brechbiel MW (2004) Antibody-targeted radiation cancer therapy Nature Rev Drug Discovery 3:488-98 doi:10.1038/nrd1413
- Rao AV, Akabani G and Rizzieri DA (2005) Radioimmunotherapy for Non-Hodgkin's Lymphoma Clin Med Res 3(3):157-65 doi:10.3121/cmr.3.3.157
- Lee ST et al (2007) BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma Expert Opin Biol Ther 7(1):113-22 doi:10.1517/14712522.214.171.124
- Schuster SJ et al (2011) Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma Journal of Clinical Oncology 29 doi: 10.1200/JCO.2010.33.3005
Last edited: 5 November 2014 10:49